OCTOBER 2020: FALL UPDATE

OCTOBER 2020: FALL UPDATE

As a result of the successful financing round of CHF 10 million in April 2020, the InnoMedica team was able to reach important milestones in the main projects Talidox and Talineuren in the last months and make progress in the…

April 2020: Capital increase with public offering

April 2020: Capital increase with public offering

Please find below the relevant investor documents (including subscription form). Information on InnoMedica and the projects TaliCoVax-19 (vaccination), Talidox (oncology) and Talineuren (neurology) can be found in the business documentation. Investor Documentation Download Business Documentation 2020   Download last year’s…

March 2020: InnoMedica launches project for corona vaccination

March 2020: InnoMedica launches project for corona vaccination

The corona pandemic is a major challenge for everyone. In this context, InnoMedica can contribute its expertise to the development of an urgently needed vaccine. InnoMedica has good contacts with the Institute for Virology and Immunology IVI in Mittelhäusern, BE…

June 2019: Annual General Meeting 2019

June 2019: Annual General Meeting 2019

The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2019. The Annual General Meeting will be held on Tuesday, June 25th  2019 at 04:30 pm (registration at 04:00 pm) in the Careum Auditorium – Pestalozzistrasse 11, 8032 Zürich. Shareholders will be admitted…

May 2019: Talidox better tolerated than expected

May 2019: Talidox better tolerated than expected

On May 14, 2019, the sixth patient was treated with Talidox at the Inselspital Bern. The dose of 40mg/m2 now reached already corresponds to the maximum dose originally planned in the study. The latter was defined on the basis of…

April - May 2019: CAPITAL INCREASE WITH PUBLIC OFFERING

April – May 2019: CAPITAL INCREASE WITH PUBLIC OFFERING

Capital increase with public offering of 103,516 bearer shares / CHF 23,456,725.60 The subscription ends May 31st 2019. Share price is CHF 226.60 per new share (minimum 60 shares).   Visit us at an investor event in Bern, Zurich, Basel, St. Gallen,…

January 2019: Resignations from the Board of Directors

The two Board members Dr. Herbert Früh and Manuel Frick resigned from the Board of Directors of InnoMedica Holding AG as of mid-January 2019. Herbert Früh has been a member of the Board of Directors since 2000 and acting as…

December Update 2018

December Update 2018

Thanks to the successful financing round of CHF 10.25 million in May 2018, the InnoMedica team reached an important milestone with Talidox with the start of the clinical trial and made strategically relevant progress in clinical development and raw material…

November 2018: Start of the clinical trial with Talidox

November 2018: Start of the clinical trial with Talidox

Swissmedic has approved the clinical study phase I with Talidox. After production met all pharmaceutical standards, InnoMedica’s quality assurance released Talidox for clinical use. Last Monday, November 12, 2018, the first cancer patient was treated with Talidox at the Cantonal…

June 2018: Annual General Meeting 2018

June 2018: Annual General Meeting 2018

The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2018. The Annual General Meeting will be held on Tuesday, June 26th  2018 at 04:30 pm (doors open at 04:15 pm) in the Careum Auditorium – Pestalozzistrasse 11, 8032 Zürich. Shareholders…